公开(公告)号：WO2021201310A1

公开(公告)日：2021-10-07

申请号：PCT/KR2020/004318

申请日：2020-03-30

Applicant: 현대바이오사이언스 주식회사 ,  (주)위바이오트리

Inventor： 김호준 ,  전용주

IPC: A61K8/14 ,  A61K8/64 ,  A61K8/44 ,  A61K8/34 ,  A61K8/67 ,  A61K8/42 ,  A61Q7/00 ,  A61K31/16 ,  A61K31/355 ,  A61K31/375 ,  A61K8/11 ,  A61K8/553 ,  A61K8/673 ,  A61K8/676 ,  A61K8/678 ,  A61K9/1271 ,  A61K9/5015 ,  A61K9/5052 ,  A61P17/14

Abstract: 본 발명은 비타민과 덱스판테놀이 봉입된 에토좀을 포함하는 에토좀 조성물로서, 상기 에토좀은 에탄올, 펩티드, 포스파티틸콜린(Phosphatidyl choline), 아미노산 화합물을 포함하는 에토좀 조성물 및 이의 제조방법에 관한 것이다. [대표도] 도6

公开(公告)号：WO2022159205A2

公开(公告)日：2022-07-28

申请号：PCT/US2021/062845

申请日：2021-12-10

Applicant: AMNEAL COMPLEX PRODUCTS RESEARCH LLC

Inventor： VAKA, Siva, Ram Kiran ,  DESAL, Dipen ,  SHAH, Navnit, H. ,  PHUAPRADIT, Wantanee ,  SHELKE, Namdev, B.

IPC: A61K9/20 ,  A61K9/28 ,  A61K9/50 ,  A61K31/4425 ,  A61K9/0004 ,  A61K9/0065 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2022 ,  A61K9/2027 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/2813 ,  A61K9/282 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5031 ,  A61K9/5042 ,  A61K9/5073 ,  A61K9/5078

Abstract: The present disclosure provides extended release pyridostigmine compositions for symptomatic treatment of myasthenia gravis; pretreatment for exposure to the chemical nerve agent Soman; and/or the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure),. The compositions of the disclosure provide reduced Fluctuation Index; reduced/blunted Cmax; higher Cmin, reduced Cmax: Cmin ratio, and reduced initial burst release of the drug, as compared to marketed pyridostigmine products. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs.

公开(公告)号：WO2020172629A1

公开(公告)日：2020-08-27

申请号：PCT/US2020/019361

申请日：2020-02-21

Applicant: CHROMADEX INC.

Inventor： ERICKSON, Aron ,  REDPATH, Philip ,  ROBERTS, Matthew ,  STORJOHANN, Amanda

IPC: C07H19/048 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/44 ,  C07H19/04 ,  A23L33/115 ,  A23L33/13 ,  A61K45/06 ,  A61K47/44 ,  A61K9/0056 ,  A61K9/14 ,  A61K9/148 ,  A61K9/1617 ,  A61K9/5015

Abstract: Methods for stabilizing or encapsulating at least one compound selected from the group consisting of nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), derivatives thereof, or salts thereof, are provided. Compositions including wax prills, stabilized, or encapsulated forms of at least one compound selected from the group consisting of nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, are also provided.

公开(公告)号：WO2023057451A1

公开(公告)日：2023-04-13

申请号：PCT/EP2022/077586

申请日：2022-10-04

Applicant: HERMES PHARMA GMBH

Inventor： WEISS, Gerd ,  HAALA, Josef ,  SCHIEMENZ, Wolfgang

IPC: A61K9/50 ,  A61K33/06 ,  A61K9/00 ,  A23L33/16 ,  A61K9/0056 ,  A61K9/5015 ,  A61K9/5084 ,  A61K9/5089

Abstract: Erfindungsgemäß wird ein orales Direktgranulat, welches eine kontrollierte Magnesium-Freisetzung mit sowohl retardierten als auch nicht-retardierten Anteilen ermöglicht. Das Granulat enthält unter anderem Retardpartikel mit einem magnesiumhaltigen Kern und einem lipophilen Überzug, wobei mindestens die Kerne dieser Retardpartikel eine vorgegebene Abriebfestigkeit aufweisen, welche mittels Vibrationssiebung über einen Zeitraum von 60 Minuten bestimmt wird und welche eine Schmelzbeschichtung dieser Kerne ermöglicht, insbesondere eine Schmelzbeschichtung mit Lipiden in der Wirbelschicht. Die Erfindung stellt ferner eine Methode zur Charakterisierung der Magnesium-haltigen Kerne bereit, sowie ein Verfahren zur Herstellung der Retardpartikel mittels Schmelzbeschichtung (Hot-Melt-Coating).

公开(公告)号：WO2022024126A2

公开(公告)日：2022-02-03

申请号：PCT/IL2021/050914

申请日：2021-07-29

Applicant: KARNAK TECHNOLOGIES, LLC ,  EZRA, Rafael

Inventor： EZRA, Rafael

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/50 ,  A23L29/206 ,  A23L29/262 ,  A23L29/30 ,  A23L33/10 ,  A23L33/30 ,  A23P10/35 ,  A23P10/47 ,  A61K31/01 ,  A61K31/05 ,  A61K31/352 ,  A61K31/593 ,  A61K36/185 ,  A61K36/53 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1664 ,  A61K9/1694 ,  A61K9/19 ,  A61K9/5015 ,  A61K9/5084

Abstract: The invention provides compositions that increase oral bioavailability of edible lipophilic substances such as beneficial edible oils, oil-soluble vitamins, and nutraceuticals. The compositions and methods of the invention are highly applicable to food industries in the production of foods, beverages, supplements, and food additives.

公开(公告)号：WO2021252382A1

公开(公告)日：2021-12-16

申请号：PCT/US2021/036232

申请日：2021-06-07

Applicant: THE TEXAS A&M UNIVERSITY SYSTEM ,  WILLIAM MARSH RICE UNIVERSITY ,  THE TRUSTEES OF INDIANA UNIVERSITY

Inventor： KENT, Thomas, A. ,  DERRY, Paul, J. ,  HUSTON, David, P. ,  LIOPO, Anton, V. ,  TOUR, James, M. ,  McHUGH, Emily, M. ,  MENDOZA, Kimberly ,  OLSON, Kenneth, R. ,  KAHN, Mansoor

IPC: A61K9/14 ,  A61K47/20 ,  A61K33/44 ,  A61K9/0019 ,  A61K9/5015

Abstract: A therapeutic method for catalytically forming persulfide and/or polysulfide from hydrogen sulfide in vitro and in vivo using endogenously or exogenously released hydrogen sulfide is disclosed. That method comprises contacting cells in need including those under oxidative stress, traumatic brain injury (TBI) and hypoxia, or have an excess of hydrogen sulfide or deficiency of protein persulfidation with oxidized carbon nanoparticulate material in which the particles contain a plurality of carbonyl, hydroxyl and carboxyl substituents. Oxidized carbon nanoparticulate (OCN) material can be prepared from any of a variety of sources of which activated charcoal is preferred. A water-dispersible OCN material is described that does not need added hydrophilic polymers to provide dispersibility for at least 7 days at a concentration of about 1-5 mg/mL. These OCN materials also have a UV absorbance maximum in water of about 220 nm and pass through a 0.22 μm pore PES membrane.

公开(公告)号：WO2021141494A1

公开(公告)日：2021-07-15

申请号：PCT/NL2021/050011

申请日：2021-01-08

Applicant: STABICAN B.V.

Inventor： DE BRUIJN, Robin

IPC: A61K9/50 ,  A61K9/51 ,  A61K31/352 ,  A61K9/5015 ,  A61K9/5089 ,  A61K9/5123 ,  A61K9/5192

Abstract: The invention relates to process for preparing cannabinoid-containing particles, wherein first a solution is provided wherein the solvent has a water solubility in the range of 2–100 g/L at 25 °C and wherein the solution comprises 1) a cannabis component comprising THC; and 2) a shell-forming component comprising one or more compounds selected from the group of C10–C30 fatty alcohols, C10–C30 fatty acids and esters of C10–C30 fatty alcohols and C10–C30 fatty acids. Then, droplets of the solution are generated in an aqueous medium and the solvent is allowed to migrate from the droplets to the aqueous medium to thereby form solid particles wherein a shell of shell-forming component encapsulates the cannabis component.

公开(公告)号：WO2022219573A2

公开(公告)日：2022-10-20

申请号：PCT/IB2022/053504

申请日：2022-04-14

Applicant: ROLLING PASTURES PTE. LTD.

Inventor： TAN WEE LIAT, Leonard

IPC: A23P10/30 ,  A23L2/52 ,  A23L33/16 ,  A61K33/26 ,  A61K9/48 ,  A61K9/5015 ,  A61K9/5036 ,  A61K9/5052 ,  A61K9/5073 ,  A61K9/5089 ,  A61K9/5094

Abstract: Microencapsulation wall material of a microencapsulation product for food and beverage capsules, wherein the microencapsulation wall material comprises a hyper-polarizable hydrophilic polymer species and/or a hydrophobic polymer species, a first mixture, wherein the first mixture comprises at least one material out of the group of collagen, chitosan, silk fibroin, gelatin, alginate, modified starch and biopolymers, and a second mixture, wherein the second mixture comprises at least one material out of the group of lecithin, cyclodextrin and whey surfactant base mixture, wherein the first mixture and the second mixture form an emulsion, and edible capsule, comprising a wall comprising microencapsulation wall material and an electronic component included in the core.

公开(公告)号：WO2022212300A1

公开(公告)日：2022-10-06

申请号：PCT/US2022/022239

申请日：2022-03-29

Applicant: CELANESE EVA PERFORMANCE POLYMERS LLC

Inventor： HALEY, Jeffrey C. ,  GYANANI, Vijay ,  WILSON, Brian D. ,  PATEL, Harsh ,  DEVANATHAN, Narsi

IPC: A61K8/11 ,  A61K8/55 ,  A61K9/48 ,  A61K47/26 ,  A61K48/00 ,  C12N15/11 ,  C12N15/88 ,  A61K31/7088 ,  A61K9/5015 ,  A61K9/5123 ,  A61K9/5138

Abstract: An implantable medical device is provided. The device comprises a drug release layer, wherein the drug release layer contains particles dispersed within a polymer matrix. The lipid particles include a carrier component that contains a carrier (e.g., peptide, protein, carbohydrate, lipid, polymer, etc.) and encapsulates a nucleic acid, wherein the polymer matrix includes an ethylene vinyl acetate copolymer. The ratio of the melting temperature of the ethylene vinyl acetate copolymer to the melting temperature of the carrier is about 2 °C/°C or less.

公开(公告)号：WO2022187263A2

公开(公告)日：2022-09-09

申请号：PCT/US2022/018366

申请日：2022-03-01

Applicant: STEADMAN PHILIPPON RESEARCH INSTITUTE ,  BAHNEY, Chelsea ,  MARCUCIO, Ralph ,  FONTANA, Gianluca ,  MURPHY, William, L. ,  COOKE, John, P. ,  KISS, Daniel, L. ,  TARABALLI, Francesca ,  EHRHART, Nicole ,  NELSON, Anna-Laura

Inventor： BAHNEY, Chelsea ,  MARCUCIO, Ralph ,  FONTANA, Gianluca ,  MURPHY, William, L. ,  COOKE, John, P. ,  KISS, Daniel, L. ,  TARABALLI, Francesca ,  EHRHART, Nicole ,  NELSON, Anna-Laura

IPC: A61K9/00 ,  A61K9/50 ,  A61K9/51 ,  C12N15/113 ,  A61P19/08 ,  A61K38/00 ,  A61K31/7105 ,  A61K38/1709 ,  A61K48/0041 ,  A61K48/005 ,  A61K9/0019 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5115 ,  A61K9/5123 ,  A61P19/00 ,  C07K14/78 ,  C12N15/88 ,  C12N2800/22

Abstract: The present disclosure is related to methods of stimulating bone formation for the purpose of improving bone repair, accelerating bone healing, and/or generating new bone in a local region with absent or diminished bone due to injury, disease, or defect, comprising administering a composition comprising β-catenin mRNA complex to the subject.